Aliskiren Adverse Event Signal Strengths Across Organ Systems

Signal strength metrics for adverse events associated with the antihypertensive drug aliskiren, categorized by System Organ Class (SOC). The dataset was created by Meirong Shan and last updated in April 2026. It is a small dataset, approximately 9.5 KB in size, derived from the FDA Adverse Event Reporting System (FAERS) database.

Use Cases

• Analyze disproportionality signals for aliskiren across different System Organ Classes (SOCs).
• Identify potential adverse events (AEs) with significant signal strength for specific organ systems.
• Compare the frequency or strength of reported adverse events among 607 Preferred Terms.
• Investigate cardiovascular-related adverse event signals for aliskiren in the FAERS database.

Strengths

• Data sourced from the authoritative FDA Adverse Event Reporting System (FAERS).
• Categorizes adverse events across standardized System Organ Classes (SOCs).
• Released under a permissive CC-BY-4.0 license.

Limitations

• Extremely small dataset size of 9.5 KB indicates very limited scope and likely low record count.
• Specific row count, column names, and sample data are unavailable for assessment.
• Data is static and represents a retrospective analysis, not a live feed.

Provenance

Source

FDA Adverse Event Reporting System (FAERS) database.

Collection Method

Retrospective quantitative analysis of spontaneous adverse event reports.

Freshness

Last updated April 2026.

Geography

Primarily United States (from FAERS).